Global Omics Based Clinical Trials Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Omics Based Clinical Trials market size was valued at US$ 2309 million in 2024 and is forecast to a readjusted size of USD 3338 million by 2031 with a CAGR of 5.5% during review period.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
This report is a detailed and comprehensive analysis for global Omics Based Clinical Trials market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Omics Based Clinical Trials market size and forecasts, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Omics Based Clinical Trials
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Omics Based Clinical Trials market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance, Rebus Bio, Novo Nordisk, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Omics Based Clinical Trials market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Market segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
Market segment by players, this report covers
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Omics Based Clinical Trials product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Omics Based Clinical Trials, with revenue, gross margin, and global market share of Omics Based Clinical Trials from 2020 to 2025.
Chapter 3, the Omics Based Clinical Trials competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Omics Based Clinical Trials market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Omics Based Clinical Trials.
Chapter 13, to describe Omics Based Clinical Trials research findings and conclusion.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
This report is a detailed and comprehensive analysis for global Omics Based Clinical Trials market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Omics Based Clinical Trials market size and forecasts, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Omics Based Clinical Trials market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Omics Based Clinical Trials
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Omics Based Clinical Trials market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance, Rebus Bio, Novo Nordisk, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Omics Based Clinical Trials market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Market segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
Market segment by players, this report covers
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Omics Based Clinical Trials product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Omics Based Clinical Trials, with revenue, gross margin, and global market share of Omics Based Clinical Trials from 2020 to 2025.
Chapter 3, the Omics Based Clinical Trials competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Omics Based Clinical Trials market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Omics Based Clinical Trials.
Chapter 13, to describe Omics Based Clinical Trials research findings and conclusion.
Table of Contents
84 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
